The MedTech Business Model: Revenue Pillars, Razor/Blade, and Installed Base Economics

Introduction

Medical devices represent a fundamentally different business model from pharmaceuticals and biotech. There are no patent cliffs that wipe out 80% of a product's revenue overnight. There are no binary clinical trial outcomes that double or halve a company's market cap in a day. Instead, MedTech companies build durable competitive advantages through installed bases, surgeon training, hospital relationships, and iterative product innovation that creates long product cycles and high switching costs. Understanding how MedTech generates revenue, why the best companies earn 65-70% gross margins on what are essentially physical products, and how the business model is evolving toward software and services is essential for healthcare investment banking.

This article covers the foundational business model that drives every MedTech valuation, M&A transaction, and equity research analysis in the sector.

Every MedTech company, regardless of size or specialty, generates revenue from some combination of three pillars. The mix between these pillars determines the company's margin profile, revenue visibility, growth predictability, and ultimately its valuation multiple. Healthcare bankers assess a MedTech company's revenue quality primarily by analyzing the relative contribution of each pillar.

Capital Equipment

Capital equipment includes durable medical systems sold to hospitals and surgical centers: robotic surgery platforms, imaging scanners (MRI, CT, X-ray), patient monitors, ventilators, diagnostic analyzers, and radiation therapy systems. These are high-value, one-time purchases (typically $500,000 to $5+ million per unit) that go through hospital capital budgeting processes and often require board-level approval for large expenditures.

Capital equipment revenue is inherently lumpy and unpredictable quarter to quarter. Hospitals make purchasing decisions based on capital budgets that reset annually, and large orders can shift between quarters as hospital CFOs manage their capital allocation priorities. A single delayed or accelerated order can swing a MedTech company's quarterly revenue by $10-50 million. This lumpiness creates forecasting challenges for analysts and is one reason pure capital equipment businesses trade at lower multiples than consumable-heavy companies: investors apply a discount for revenue unpredictability.

The capital equipment sales cycle is also significantly longer than consumable sales. A decision to purchase a robotic surgery system or MRI scanner can take 6-18 months, involving clinical evaluation (surgeons and radiologists testing the equipment), financial analysis (CFO evaluating the ROI and payback period), and governance approval (board sign-off for expenditures above threshold). This long sales cycle means that capital equipment revenue pipelines are more visible in advance but also more subject to cancellation or delay.

Consumables and Disposables

Consumables are the single-use or limited-use products consumed during each procedure: surgical instruments (robotic instrument tips, stapler cartridges), implantable devices (stents, pacemaker leads), guide wires, catheters, diagnostic reagents, sensor patches, and other procedure-specific supplies. Unlike capital equipment, consumables generate recurring, per-procedure revenue that scales with procedure volume rather than hospital capital budgets.

Consumables typically carry gross margins of 60-75%, comparable to or higher than capital equipment, with significantly better revenue visibility and predictability. A hospital performing 1,200 robotic surgeries per year on an installed system will purchase instruments for every single procedure, creating a highly predictable revenue stream that can be forecasted with reasonable accuracy based on the installed base size and utilization rates.

The distinction between consumable types matters for financial modeling. Implantable consumables (orthopedic joints, cardiac stents, spine hardware) are single-use products that remain in the patient permanently. These are high-ASP products (individual implants range from $2,000 to $20,000+) with significant ASP erosion pressure from GPO negotiations and competitive entry. Disposable instruments (robotic tips, stapler cartridges, catheter sheaths) are single-use products that are discarded after the procedure. These tend to be lower ASP per unit but higher volume, with more stable pricing because they are often proprietary to a specific capital equipment platform.

Consumable Attach Rate

The ratio of consumable revenue generated per unit of installed capital equipment, typically expressed per procedure or annually. A high attach rate means each installed system generates substantial recurring revenue. Intuitive Surgical's attach rate is approximately $2,100 per procedure in instruments and accessories. With an average da Vinci system performing 200-250 procedures per year, each installed system generates roughly $420,000-$525,000 in annual consumable revenue, a stream that continues for the 7-10 year life of the system. The lifetime consumable revenue from a single installed system ($3-5 million) far exceeds the system purchase price ($1.5-2.5 million), illustrating why the installed base, not the system sale, is where the value resides.

Services

Services include maintenance contracts, software licenses, installation, training, calibration, and technical support. Service revenue is the most predictable of the three pillars (multi-year contracts with annual renewal rates above 90%, often 95%+) but also typically the smallest contributor in most MedTech companies, representing 10-20% of total revenue.

Service contracts are structured as annual or multi-year agreements that cover preventive maintenance, parts replacement, software updates, and technical support. For capital-intensive systems like MRI scanners and robotic surgery platforms, service contracts are nearly universal because hospitals cannot afford unplanned downtime (a non-functional MRI scanner costs the hospital $10,000-20,000 per day in lost procedure revenue). Service margins are attractive (40-50% operating margins) because the variable cost is primarily field service technician labor, which is leveraged across a large installed base.

Services are becoming strategically more important as MedTech companies layer software capabilities onto hardware platforms. Software-driven services (data analytics, clinical decision support, remote monitoring, AI-assisted imaging interpretation) carry near-100% gross margins and are increasingly sold as recurring subscriptions rather than one-time licenses. This shift is blurring the line between MedTech and health IT, and is a key driver of multiple expansion for companies that successfully demonstrate recurring software revenue growth.

Razor/Blade Model in MedTech

A business model where the company sells a durable capital equipment platform (the "razor") at a price that may be at, near, or even below cost, then generates ongoing high-margin revenue from proprietary consumables (the "blades") used with that platform. The capital equipment creates switching costs through surgeon training, workflow integration, and capital depreciation, locking in the consumable revenue stream for the 7-10 year life of the installed system. The model is named after Gillette's strategy of selling razor handles cheaply to drive recurring blade sales. In MedTech, the model is particularly powerful because the switching costs are much higher than consumer products: retraining a surgeon is not comparable to switching razor brands.

The razor/blade model is the single most important business model concept in MedTech. It explains why the companies with the largest installed bases and highest consumable attach rates command the highest valuations, even if their capital equipment revenue growth is modest or declining as a percentage of total revenue.

Intuitive Surgical: The Gold Standard

Intuitive Surgical is the clearest example of the razor/blade model in MedTech and one of the most frequently discussed companies in healthcare investment banking interviews. The numbers illustrate why the model is so powerful:

The key insight is that Intuitive's revenue growth is primarily driven by procedure volume growth on its installed base, not by selling more systems. Each new system sale adds to the installed base and creates a new stream of consumable revenue that compounds over time. The company added roughly 1,400 new systems in 2024, but the procedure growth across its existing 10,000+ systems generated far more incremental revenue than those new system sales. This is the compounding engine that makes the razor/blade model so valuable: the installed base grows each year, and utilization per system increases as surgeons adopt new procedure types on the platform, creating two compounding growth drivers in a single business.

Other Razor/Blade Examples Across MedTech

The model extends well beyond surgical robotics, appearing wherever capital equipment creates an installed base that drives proprietary consumable purchases:

The mix between the three revenue pillars determines a MedTech company's revenue quality, a key driver of valuation multiples and M&A attractiveness. Healthcare bankers and investors assess revenue quality through several lenses:

Recurring vs. non-recurring. Consumable and service revenue is recurring (driven by procedure volumes and maintenance contracts that renew annually). Capital equipment revenue is non-recurring and lumpy (driven by capital budgets, replacement cycles, and competitive wins/losses). A company with 80% recurring revenue is valued at a significant premium to one with 80% capital equipment revenue because recurring revenue provides greater visibility, predictability, and downside protection.

Procedure-driven vs. capital budget-driven. Procedure-driven revenue (consumables) is more resilient in economic downturns because medical procedures are largely non-discretionary. A patient with a hip fracture needs surgery regardless of the economic environment. Capital equipment purchases, however, can be deferred during budget tightening, as hospitals demonstrated during COVID-19 when imaging system purchases were delayed while device utilization for essential procedures continued.

Volume vs. price dynamics. MedTech revenue growth is predominantly volume-driven (more procedures = more consumables) rather than price-driven. Average selling prices for most device categories face structural erosion of 1-3% annually from GPO negotiations and competitive pressure. Companies must offset ASP pressure with volume growth and mix shift toward higher-acuity (higher-priced) products. This means that a MedTech company reporting 5% organic growth may actually be growing volumes at 7% while losing 2% on pricing, a decomposition that healthcare bankers must understand.

MedTech companies have a distinctive financial profile that sits between pharma (highest margins) and healthcare services (lowest margins):

Gross margins are high because of IP-protected products and manufacturing scale. A surgical stapler costs a few dollars to manufacture but sells for $200-400. A robotic instrument tip costs $30-50 to produce but sells for $200-600. The IP protection comes not from patents alone (though patents matter) but from the combination of regulatory clearance, manufacturing know-how, quality systems, and clinical data that creates barriers to entry. Even when patents expire, competitors face multi-year regulatory and manufacturing hurdles to produce equivalent products.

SG&A is elevated because of the direct sales model. Unlike pharma (which sells through wholesalers and pharmacies), MedTech companies often sell directly through clinical sales representatives who are present in the operating room during procedures. These reps provide real-time technical support to surgeons, troubleshoot instrument issues, and help optimize procedural technique. This direct sales force is expensive (a fully loaded MedTech sales rep costs $200,000-350,000 annually including salary, commission, car, travel, and benefits) but creates deep physician relationships and significant switching costs. Companies with 5,000+ field sales reps spend 30-35% of revenue on SG&A.

R&D intensity is moderate. MedTech R&D spending (6-15% of revenue) is lower than pharma (15-25%) because device development cycles are shorter (3-5 years vs. 10-15 for drugs), clinical studies are smaller and less expensive (device trials typically enroll hundreds of patients vs. thousands for drugs), and iterative improvement (next-generation devices) is more common than de novo discovery. The regulatory pathway also contributes: 510(k) clearance (the most common pathway) leverages predicate device equivalence, reducing the clinical evidence burden compared to pharma's NDA/BLA pathway.

Medical Device as a Service (MDaaS)

Some MedTech companies are shifting from selling capital equipment outright to offering it as a service, with hospitals paying per-procedure or monthly subscription fees instead of making large upfront capital purchases. This model converts lumpy capital revenue into predictable recurring revenue but requires the MedTech company to carry the asset on its balance sheet (increasing capital intensity) and to manage asset utilization risk.

Siemens Healthineers has been a leader in this shift, offering imaging equipment through managed service contracts where hospitals pay per scan rather than purchasing the system outright. The model benefits hospitals by lowering barriers to adoption (no large capital outlay or board approval needed), provides technology refresh cycles (the contract can include equipment upgrades), and increases MedTech revenue predictability. For the MedTech company, the model often generates higher lifetime revenue per system than an outright sale because the per-scan pricing captures a service premium over the equipment's useful life.

Software and Data Monetization

The most significant long-term business model evolution in MedTech is the layering of software onto hardware platforms. Connected devices generate data that can be analyzed to improve clinical outcomes, optimize hospital operations, and enable remote patient monitoring. This data creates new revenue streams with software-like margins (85-95% gross margins) that dramatically enhance the economics of the installed base.

The next article covers the regulatory pathways that determine how devices reach the market, including the critical distinction between 510(k), PMA, and De Novo classification.